Procedures
ADVERSE EVENTS
Each treatment cycle consisted of 21 days. Patients received tislelizumab intravenously at a fixed dose of 200 mg on day 1 of each cycle. Previous to the first infusion of tislelizumab, a pre-medication with an antihistamine and paracetamol was permitted, in addition to oral or intravenous glucocorticoids if considered indicated by the investigator. The first infusion was administered over 60 min and subsequent infusions over 30 min. Zanubrutinib was administered orally at a fixed dose of 160 mg twice daily from day 1 onwards. Dose modifications or interruptions were permitted for management of adverse events. Before the induction phase, a pre-phase therapy with steroids, vincristine (up to 2 mg intravenously) or cyclophosphamide (up to 200 mg